



Advances in Autologous PRP Therapy

Guest Editor:

Dr. Jeremy Magalon

1. Cell Therapy Department, Marseille University Hospital, APHM, 13005 Marseille, France
2. Center of Cardiovascular Research & Nutrition, Pharmacy Faculty, Aix Marseille University, 13385 Marseille, France
3. Bioengineering Department, Pharmacy Faculty, Aix Marseille University, 13385 Marseille, France

Deadline for manuscript submissions:

closed (31 August 2023)

Message from the Guest Editor

Autologous PRP therapies have been used for more than 30 years, resulting in considerable interest in the field of regenerative medicine among diverse specialties. On one hand, PRP therapies are becoming suitable treatment options with clinical benefits and encouraging patient outcomes reported. On the other hand, production heterogeneity of PRP, the absence of systematic and standardized biological characterization, and an unclear mechanism of action have led to controversial results compared to other reference treatments and contributed to the fact that this therapy is struggling to be recognized as effective by the learned societies and still not covered by insurance companies.

This Special Issue of Bioengineering, will focus on recent advances in autologous PRP therapy research for therapeutic purposes, with no limit regarding the specialties using PRP. The research work submitted may be in vitro or in vivo experiments with a special interest for papers focusing on comprehension of PRP and platelets extracellular vesicles mechanism of action, as well as clinical studies, case series, or real-life studies in a context of therapeutic use.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Anthony Guiseppi-Elie

Department of Biomedical
Engineering, Texas A&M
University, College Station, TX
77843, USA

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Bioengineering* (ISSN 2306-5354). *Bioengineering* is published in open access format – research articles, reviews and other contents are released on the Internet immediately after acceptance. The scientific community and the general public have unlimited and free access to the content as soon as it is published. *Bioengineering* provides an advanced forum for the science and technology of bioengineering. We would be pleased to welcome you as one of our authors.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, Inspec, and other databases.

Journal Rank: JCR - Q2 (*Engineering, Biomedical*)

Rapid Publication: manuscripts are peer-reviewed and a first decision is provided to authors approximately 15.6 days after submission; acceptance to publication is undertaken in 3.1 days (median values for papers published in this journal in the first half of 2024).

Contact Us

Bioengineering Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/bioengineering
bioengineering@mdpi.com
[X@Bioeng_MDPI](https://twitter.com/Bioeng_MDPI)